Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.

Enbrel (etanercept) is a brand-name subcutaneous injection prescribed for psoriatic arthritis (PsA) in adults and juvenile PsA in some children. This article covers topics such as side effects ...

Biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) seem to be the most effective treatments for ...

Psoriatic arthritis (PsA) is an autoimmune disease ... Half received a 150 milligram (mg) shot of risankizumab at the start of the trial, one month later, and three months after that.

Biocon had entered into a settlement and licensing agreement with Janssen Biotech Inc, Janssen Sciences Ireland and Johnson & ...

After the launch of Ustekinumab, a biosimilar of Stelara, in the United States and Europe, Biocon Biologics’ biosimilar drug ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

Pyzchiva® is a key biosimilar value driver for the Sandoz growth strategy. It has been launched in 23 markets in Europe. The autoinjector is now available in Spain and will continue to roll out across ...

Sandoz launches ustekinumab biosimilar, Pyzchiva autoinjector in Europe: Basel Saturday, May 24, 2025, 12:00 Hrs [IST] Sandoz, one of the global leaders in generic and biosimilar ...

Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in ...

Biocon Biologics and Yoshindo expand access to ustekinumab biosimilar in Japan: Our Bureau, Bengaluru Wednesday, May 21, 2025, 15:15 Hrs [IST] Biocon Biologics a fully integrated ...